| 臺大學術典藏 |
2022-08-19T00:20:45Z |
A decade of changes in preferences for life-sustaining treatments among terminally ill patients with cancer
|
Chiang M.-C.; Liu L.N.; Sung Y.-C.; Hsieh C.-I.; Chang S.-Y.; Chang Y.-H.; Chang C.-S.; CHIUN HSU; Wen F.-H.; Liu T.-W.; Tang S.T. |
| 臺大學術典藏 |
2022-08-19T00:20:45Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Cheng A.-L.; Han K.-H.; Jia J.-D.; Seong J.; CHIUN HSU; Chen B.-B.; Chen C.-H.; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W. |
| 臺大學術典藏 |
2022-08-19T00:20:44Z |
Cough with bile
|
Liu K.-L.; CHIUN HSU; Chang C.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:44Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; CHIUN HSU; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-08-19T00:20:43Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Ou D.-L.; Cheng A.-L.; Shao Y.-Y.; Feng Z.-R.; Lin L.-I.; Cheng Y.-C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:43Z |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer
|
Chiang N.-J.; CHIUN HSU; Chen J.-S.; Tsou H.-H.; Shen Y.-Y.; Chao Y.; Chen M.-H.; Yeh T.-S.; Shan Y.-S.; Huang S.-F.; Chen L.-T. |
| 臺大學術典藏 |
2022-08-19T00:20:42Z |
Epithelioid Trophoblastic Tumor Around an Abdominal Cesarean Scar: A Pathologic and Molecular Genetic Analysis
|
Hsiue E.H.-C.; CHIUN HSU; Tseng L.-H.; Lu T.-P.; Kuo K.-T. |
| 臺大學術典藏 |
2022-08-19T00:20:42Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
CHIUN HSU; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H.; Guo J.-C.; Kuo T.-C.; Wu H.; Yang S.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:41Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; CHIUN HSU; Hsu C.-H.; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
CHIUN HSU; Ou D.-L.; Cheng A.-L.; Chen C.-W.; Tan C.-T.; Lin Y.-Y. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
CHIUN HSU; Wang M.-J.; Cheng A.-L.; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYnote-028 study
|
Hansen A.R.; Cheng J.D.; Thanigaimani P.; Saraf S.; CHIUN HSU; Lee S.-H.; Ejadi S.; Even C.; Cohen R.B.; Le Tourneau C.; Mehnert J.M.; Algazi A.; Van Brummelen E.M.J. |
| 臺大學術典藏 |
2022-08-19T00:20:39Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
CHIUN HSU; Taiwan Cooperative Oncology Group; Liu T.-W.; Chen P.-J.; Cheng A.-L.; Lin J.; Yuan Q.; Xia N.; Yao M.; Lin S.-J.; Chen J.-H.; Chang C.-S.; Pei S.-N.; Tsou H.-H.; Yang H.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:39Z |
Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis
|
Liu Q.; Lin A.-H.; Tang L.-L.; Sun Y.; Ma J.; CHIUN HSU; Mao Y.-P.; Li W.-F.; Zhou G.-Q.; Chen L.; Huang C.-L.; Liu J.-Q.; Du X.-J.; Chen Y.-P.; Xu C. |
| 臺大學術典藏 |
2022-08-19T00:20:39Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group; Ni Y.-H.; Lin C.-L.; Hsu Y.-C.; Hsu C.-W.; Wu C.-Y.; Wu J.-C.; Cheng J.C.-H.; Leung S.W.; Chen S.-W.; Hsu H.-C.; Hong J.-H.; Wang P.-M.; Wang P.-M.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; CHIUN HSU; Chao Y.; Chen L.-T.; Lee P.-H.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Hung C.-F.; Huang S.-F.; Yang S.-S.; Chen R.-C.; Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N. |
| 臺大學術典藏 |
2022-08-19T00:20:38Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; CHIUN HSU; Lin Z.-Z.; Liu T.-H.; Shao Y.-Y.; Lu L.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:38Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Hsu P.-N.; Cheng A.-L.; CHIUN HSU; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu C.-L.; Lin Y.-Y.; Ou D.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:37Z |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M.; Ikeda M.; Chopra A.; Numata K.; Yeo W.; Kang Y.-K.; Hou M.-M.; Kim T.-Y.; Choo S.-P.; CHIUN HSU; Yau T. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
Yeh K.-H.; Cheng A.-L.; Tien Y.-W.; Kuo S.-H.; CHIUN HSU; Yang S.-H.; Guo J.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Corrigendum to ��Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis�� [J Hepatol 71 (2019) 543�V552](S0168827819303009)(10.1016/j.jhep.2019.05.014)
|
Kudo M.; Dela Cruz C.; Anderson J.; Zhao H.; Chao Y.; Moriguchi M.; Kuromatsu R.; Ikeda M.; Yeo W.; Chopra A.; Yau T.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Liu T.-H.; CHIUN HSU; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Cheng A.-L.; CHIUN HSU; Taiwan Cooperative Oncology Group; Chen P.-J.; Tsui C.-W.; Wu H.-Y.; Hsu Y.-T.; Chuang M.-H.; Hsiung C.A.; Liu T.-W.; Yang H.-C.; Hsiao C.-F.; Tsou H.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:35Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
Cheng A.-L.; CHIUN HSU; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2022-08-19T00:20:34Z |
An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas
|
Chen M.-H.; Chou W.-C.; Hsiao C.-F.; Jiang S.S.; Tsai H.-J.; Liu Y.-C.; CHIUN HSU; Shan Y.-S.; Hung Y.-P.; Hsich C.-H.; Chiu C.-H.; Liu T.-C.; Cho S.-F.; Liu T.-W.; Chao Y. |
| 臺大學術典藏 |
2022-08-19T00:20:34Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; Yen Y.; Hsu C.-H.; Tabernero J.; Shen Y.-C.; CHIUN HSU; Chen S.-C.; Huang Y.-H.; Yen C.-J.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Pentheroudakis G.; Cheng A.-L.; Chen L.-T.; Martinelli E. |
| 臺大學術典藏 |
2022-08-19T00:20:33Z |
Pembrolizumab for the treatment of programmed death�Vligand 1?positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYnote-028 study
|
?lez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A.; Mehnert J.M.; Bergsland E.; O��Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; CHIUN HSU; Le Tourneau C.; Hollebecque A. |
| 臺大學術典藏 |
2022-08-19T00:20:33Z |
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
|
Tebbutt N.; Strickler J.; Stein S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Dev A.; Davis S.L.; Chung H.C.; Chen J.-S.; Chao Y.; Bendell J.; Bang Y.-J.; Lee K.-H.; He A.R.; Wang Y.; Liu B.; Abdullah H.; Hack S.P.; Spahn J.; Lee M.S.; Ryoo B.-Y.; Hsu C.-H.; Numata K.; Stein S.; Verret W. |
| 臺大學術典藏 |
2022-08-19T00:20:32Z |
Novel systemic therapy for hepatocellular carcinoma
|
Dong Y.; Liu T.-H.; Yau T.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:31Z |
Fully digital problem-based learning for undergraduate medical students during the COVID-19 period: Practical considerations
|
Chao C.-T.; Tsai C.-L.; CHIUN HSU; Sheu B.-C.; Lin M.-W.; Yang C.-W.; Ho C.-C.; Chen H.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:31Z |
Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
|
CHIUN HSU; Rimassa L.; Sun H.-C.; Vogel A.; Kaseb A.O. |
| 臺大學術典藏 |
2022-08-19T00:20:31Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Lin C.-C.; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:30Z |
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
|
Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; Cheng A.-L.; Yang M.-H.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:30Z |
Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
|
Hung Y.-P.; Shao Y.-Y.; Lee J.-M.; CHIUN HSU; Hsu C.-H.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2022-08-19T00:20:28Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.; CHIUN HSU; Lee J.-M.; Chao Y.; Shao Y.-Y.; Hsu C.-H.; Yang M.-H. |
| 臺大學術典藏 |
2022-08-19T00:20:28Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Sun N.-Y.; CHIUN HSU; Cheng A.-L.; Shao Y.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.-H.; Hsu H.-C.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-08-19T00:20:28Z |
Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives
|
Su Y.-Y.; Lin Y.-J.; Li C.-C.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:27Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Lin Z.-Z.; Hsu C.-H.; Liang P.-C.; Chen B.-B.; Shao Y.-Y.; CHIUN HSU; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-08-19T00:20:27Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Lin Z.-Z.; Cheng A.-L.; Shih T.T.-F.; Chen B.-B.; Shao Y.-Y.; Hsu C.-H.; CHIUN HSU; Liang P.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:26Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang F.-C.; Lin W.-C.; Chiang W.-C.; Chen T.W.-W.; Huang T.T.-M.; Liu J.-S.; Chen Y.-M.; CHIUN HSU; Yeh K.-H.; Chu T.-S. |
| 臺大學術典藏 |
2022-08-19T00:20:26Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
CHIUN HSU; Shao Y.-Y.; Chen C.-H.; Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.-H.; Lin Z.-Z.; Lu L.-C.; Liu T.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:25Z |
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
|
Jian C.-Z.; Ou P.-Y.; Ou D.-L.; Hsieh C.-H.; Lin L.-I.; Low G.-S.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:25Z |
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma
|
Liang P.-C.; Liu T.-H.; Lu L.-C.; CHIUN HSU; Shao Y.-Y.; Chen B.-B.; Shih T.T.-F.; Shen Y.-C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:24Z |
Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma
|
Yang S.-H.; Kuo S.-H.; Bai L.-Y.; Lee J.-C.; Chen B.-B.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-19T00:20:24Z |
AXL and MET in Hepatocellular Carcinoma: A Systematic Literature review
|
Huang Y.-H.; CHIUN HSU; Hsu C.-H.; Lin S.-M. |
| 臺大學術典藏 |
2022-08-19T00:20:23Z |
Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma
|
Shao Y.-Y.; Lin L.-I.; Ling A.; CHIUN HSU; Chen P.-S.; Lee B.-S.; Cheng A.-L.; Ou D.-L. |
| 臺大學術典藏 |
2022-08-19T00:20:19Z |
Effectiveness of tutor shadowing on faculty development in problem-based learning
|
Chao C.-T.; Ho C.-C.; Sheu B.-C.; Yang C.-W.; Tsai C.-L.; Chiu Y.-L.; Lin M.-W.; Chen H.-L.; CHIUN HSU |
| 臺大學術典藏 |
2022-06-17T01:46:49Z |
Fully digital problem-based learning for undergraduate medical students during the COVID-19 period: Practical considerations
|
Chao, Chia-Ter; Tsai, Chiao-Lin; Lin, Mong-Wei; Yang, Chih-Wei; Ho, Chao-Chi; Chen, Huey-Ling; CHIUN HSU; BOR-CHING SHEU |
| 臺大學術典藏 |
2022-06-14T23:24:22Z |
Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma
|
Yang, Shih Hung; JEN-CHIEH LEE; BANG-BIN CHEN; SUNG-HSIN KUO; CHIUN HSU; Bai, Li Yuan |
| 臺大學術典藏 |
2022-05-13T02:31:29Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang, Fan-Chi; Chen, Tom Wei-Wu; TAO-MIN HUANG; Lin, Wei-Chou; Liu, Jia-Sin; Chiang, Wen-Chih; Chen, Yung-Ming; CHIUN HSU; Yeh, Kun-Huei; Chu, Tzong-Shinn |
| 臺大學術典藏 |
2022-05-12T07:39:41Z |
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
|
Hsieh, Ching-Hung; Jian, Cheng-Zhe; LIANG-IN LIN; Low, Guan-Sian; Ou, Ping-Yun; CHIUN HSU; Ou, Da-Liang |
